Psychedelics – News and Features
News
Brain circuit involved in party drug's antidepressant effect identified
At its best, the drug ketamine relieves depression within two hours and its beneficial effect on patients may last a week. At its worst, ketamine, the party drug "Special K," is addictive and may send recreational users into hallucinations and delusions.
News
LSD changes consciousness by reorganizing human brain networks
LSD is known to cause changes in consciousness, including "ego-dissolution", or a loss of the sense of self. Despite a detailed knowledge of the action of LSD at specific serotonin receptors, it has not been understood how this these pharmacological effects can translate into such a profound effect on consciousness.
News
Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients
A single dose of psilocybin, the major hallucinogenic component in magic mushrooms, induces long-lasting decreases in anxiety and depression in patients diagnosed with life-threatening cancer according to a new study presented at the annual meeting of the American College of Neuropsychopharmacology that took place Dec.
News
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Article
“Special K” could offer new hope for treatment-resistant depression
Over the past several decades, the pharmaceutical industry has been abandoning the research and development of treatments for psychiatric disorders, despite the ever-growing need for novel, more efficacious, and better targeted therapeutics.
News
Psychedelic therapy re-emerging for anxiety, PTSD and addiction
Renewed medical interest in the use of psychedelic drugs for anxiety, posttraumatic stress disorder (PTSD) and addiction has resulted in small research studies that show some success with the controlled use of these drugs, according to an analysis published in CMAJ (Canadian Medical Association Journal).
News
Allergan to Acquire Naurex
The acquisition will strengthen Allergan's long-term growth profile with the addition of Naurex's lead development product rapastinel (GLYX-13), a once-weekly intravenous Phase 3-ready molecule that has demonstrated rapid, robust and sustained efficacy in multiple Phase 2 clinical studies in depression.
News
This Week on NeuroScientistNews: 06 July – 10 July
LSD-induced synesthesia; stress resiliency and susceptibility; bacterial biofilms and MS, and more.
Article
Trippy research: Chemically-induced synesthesia
In April 1943, scientist Albert Hoffman ingested 250 micrograms of a substance he had synthesized five years prior. Less than an hour later, he “perceived an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.
News
The ecstasy and the agony: compression studies of MDMA
MDMA (3,4-methyenedioxymethamphetamine), a Class A substance that is usually found in a tableted form, is a psychoactive drug which is structurally similar to methylamphetamine and acts as a central nervous system stimulant, producing mood enhancement, increased energy and other empathetic effects.
Advertisement